Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30759366 | 1.00 | ITGA4 (0.51) | ITGA4ITGB7ATMKLK5POLB | |
| SCHEMBL487422 | 1.00 | ITGA4 (0.51) | ITGA4ITGB7ATMKLK5POLB | |
| Trifluoromethanesulfonic Acid SCHEMBL8695611 | 0.89 | ITGA4 (0.44) | ITGA4ITGB7ATMKLK5POLB | |
| SCHEMBL4025857 | 0.85 | ESR1 (0.47) | ITGA4ITGB7CTSSCTSKSLC7A5 | |
| SCHEMBL9160311 | 0.84 | ITGA4 (0.52) | ITGA4ITGB7ATMKLK5POLB | |
| SCHEMBL3425339 | 0.84 | ATM (0.51) | ITGA4ITGB7ATMKLK5CTSS | |
| SCHEMBL22442929 | 0.83 | ADRB2 (0.40) | ITGA4ITGB7ATMKLK5CYP1A2 | |
| SCHEMBL487446 | 0.83 | CTSK (0.49) | ITGA4ITGB7TDP1CTSSCTSK | |
| SCHEMBL487448 | 0.83 | CTSK (0.49) | ITGA4ITGB7TDP1CTSSCTSK | |
| SCHEMBL13108100 | 0.83 | ITGA4 (0.51) | ITGA4ITGB7ATMKLK5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048002-A1 | TOPICAL SKIN CARE COMPOSITION | MARY KAY INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11554171-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-1767185-B2 | Core shell capsules containing an oil or waxy solid | TAKASAGO PERFUMERY CO LTD (JP) | 2018-11-28 | — | — | EP | disclosed |
| EP-3337476-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| EP-1894603-B1 | Encapsulation of bulky fragrance molecules | TAKASAGO PERFUMERY CO LTD (JP) | 2014-11-19 | — | — | EP | disclosed |
| EP-1767185-A1 | Core shell capsules containing an oil or waxy solid | Takasago International Corporation (JP) | 2007-03-28 | — | — | EP | disclosed |
| US-20060160862-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-20 | — | — | US | disclosed |
| WO-2006057961-A1 | 3-[2-(3-ACYLAMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| US-5846956-A | Amino acids derivatives, the process for their preparation and their applications to therapy | SOCIETE CIVILE BIOPROJET (FR) | 1998-12-08 | — | — | US | disclosed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | disclosed |
| US-5670531-A | ENKEPHALINASE OR ANGIOTENSIN CONVERTING ENZYME INHIBITORS | SOCIETE CIVILE BIOPROJET (FR) | 1997-09-23 | — | — | US | disclosed |
| US-5599951-A | ENZYME INHIBITORS | SOCIETE CIVILE BIOPROJET (FR) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048002-A1 | TOPICAL SKIN CARE COMPOSITION | CUTA, SMURF1, AGER | ITGA4 2191/4885ITGB7 3949/4885ATM 911/4885 |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | ITGA4 4611/4885ITGB7 4462/4885ATM 2985/4885 |
| US-11554171-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | ITGA4 4611/4885ITGB7 4462/4885ATM 2985/4885 |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | ITGA4 4611/4885ITGB7 4462/4885ATM 2985/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | ITGA4 4611/4885ITGB7 4462/4885ATM 2985/4885 |
| US-20060160862-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | ITGA4 4364/4885ITGB7 4070/4885ATM 1478/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | ITGA4 4611/4885ITGB7 4462/4885ATM 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.